Key Highlights
- Travere Therapeutics (TVTX) shares rallied 44% following FDA clearance of FILSPARI for treating FSGS, a rare kidney condition
- FILSPARI represents the inaugural FDA-approved medication specifically designed for FSGS treatment
- The regulatory clearance includes both adult patients and pediatric patients starting at age 8 who present without nephrotic syndrome
- More than 30,000 patients in the United States qualify for this treatment based on current estimates
- Guggenheim analysts increased their TVTX price target from $49 to $54 while reaffirming a Buy recommendation
Travere Therapeutics (TVTX) experienced a remarkable 44% share price increase on Tuesday following the Food and Drug Administration’s approval of FILSPARI (sparsentan) for treating focal segmental glomerulosclerosis — a rare kidney condition that previously had zero approved treatment options.
Travere Therapeutics, Inc., TVTX
The regulatory approval encompasses adult patients along with pediatric patients aged 8 years and older diagnosed with FSGS who present without nephrotic syndrome. FILSPARI now holds the distinction of being the sole FDA-approved medication available for FSGS treatment.
This approval represents the second rare kidney disease indication granted for FILSPARI, which previously received authorization for treating IgA nephropathy.
According to Travere’s estimates, more than 30,000 FSGS patients across the United States meet the eligibility requirements — specifically those who do not exhibit all three concurrent nephrotic syndrome markers.
Clinical Trial Results Explained
The FDA’s decision drew support from the Phase 3 DUPLEX Study, recognized as the most extensive interventional clinical trial ever conducted in FSGS research.
Patients receiving FILSPARI demonstrated a 46% decrease in proteinuria levels measured from baseline through Week 108. Participants taking the comparison medication, maximum-dose irbesartan, experienced a 30% decrease.
Among the subset of participants specifically without nephrotic syndrome, FILSPARI achieved a 48% proteinuria reduction compared to 27% for irbesartan-treated patients.
Patients in this group receiving FILSPARI also demonstrated improved eGFR outcomes, showing a treatment difference of 1.1 mL/min/1.73 m² measured at Week 108.
The medication demonstrated a safety profile that matched irbesartan across both adult and pediatric participant groups — a favorable outcome that will support commercial adoption.
Wall Street Response
Guggenheim analyst Vamil Divan increased his TVTX price target from $49 to $54 while maintaining a Buy recommendation in response to the announcement.
Divan highlighted that the final approved label exceeded expectations, emphasizing that the cleared patient population proved broader than Wall Street had anticipated.
The label explicitly includes both primary and secondary FSGS cases — expanding beyond just the primary and genetic variants that analysts and company management had previously modeled as the core addressable market.
This expanded coverage creates a substantially larger commercial opportunity than many market participants had factored into their valuations.
TipRanks reports an additional analyst Buy recommendation with a $47 price target on the shares, while rating the technical sentiment indicator as a Buy.
TVTX’s market capitalization reached approximately $2.67 billion following Tuesday’s trading activity.
The FDA approval announcement came on April 13, 2026, with the corresponding stock movement occurring during Tuesday’s market session.
